StockNews.com Begins Coverage on Nevro (NYSE:NVRO)

StockNews.com began coverage on shares of Nevro (NYSE:NVRO) in a research report released on Wednesday. The brokerage issued a hold rating on the medical equipment provider’s stock.

Several other research firms also recently weighed in on NVRO. Robert W. Baird raised their price objective on Nevro from $5.00 to $6.00 and gave the company a “neutral” rating in a research note on Tuesday, November 12th. JMP Securities reiterated a “market perform” rating on shares of Nevro in a report on Tuesday, November 12th. Citigroup dropped their price target on Nevro from $6.00 to $5.00 and set a “neutral” rating for the company in a research report on Wednesday, December 11th. Jefferies Financial Group raised Nevro from an “underperform” rating to a “hold” rating and raised their price target for the stock from $4.50 to $5.85 in a research report on Monday, February 10th. Finally, Truist Financial dropped their price target on Nevro from $7.00 to $4.70 and set a “hold” rating for the company in a research report on Wednesday, December 18th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $6.43.

Nevro Stock Performance

NYSE NVRO opened at $5.73 on Wednesday. Nevro has a 1-year low of $3.16 and a 1-year high of $15.98. The company has a market capitalization of $214.53 million, a P/E ratio of -3.03 and a beta of 0.91. The business has a 50 day moving average price of $4.74 and a 200 day moving average price of $4.93. The company has a debt-to-equity ratio of 0.67, a current ratio of 5.02 and a quick ratio of 3.76.

Institutional Investors Weigh In On Nevro

Hedge funds and other institutional investors have recently made changes to their positions in the business. Amundi purchased a new stake in shares of Nevro in the fourth quarter valued at $30,000. Oxford Asset Management LLP purchased a new stake in shares of Nevro in the fourth quarter valued at $39,000. Corton Capital Inc. purchased a new stake in shares of Nevro in the fourth quarter valued at $43,000. Headlands Technologies LLC purchased a new stake in shares of Nevro in the fourth quarter valued at $45,000. Finally, Ieq Capital LLC purchased a new stake in shares of Nevro in the fourth quarter valued at $46,000. Hedge funds and other institutional investors own 95.52% of the company’s stock.

Nevro Company Profile

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.